|
In
a filing in Manhattan federal court, Shkreli said he has
complied with the February 2022 ban "as extensively as possible
and in good faith," and has provided the materials sought by the
Federal Trade Commission (FTC) and seven states.
The ban also included a $64.6 million civil fine, which Shkreli
said he is "so far unable" to pay. He said he intended to comply
fully with the ban and provide requested information.
Spokespeople for the FTC did not immediately respond to requests
for comment.
The FTC had accused Shkreli last month of failing to provide
information about Druglike Inc, a company it said he formed last
July.
In Friday's filing, Shkreli said he never had an ownership stake
or executive role at Druglike, which he believed has been
dissolved, and that he hoped to raise money for its successor DL
Software, which he co-founded.
He also said Druglike and DL Software were "software companies
creating professional software for chemists and physicists," and
thus outside his pharmaceutical industry ban.
Shkreli became known as "pharma bro" after raising the price of
the anti-parisitic drug Daraprim to $750 per tablet from $17.50
in 2015, and appearing unapologetic when criticized.
The lifetime ban related to Shkreli's efforts to keep generic
versions of Daraprim off the market.
U.S. District Judge Denise Cote, who imposed the ban and $64.6
million penalty, will decide the FTC contempt motion. The states
joining the motion are New York, California, Illinois, North
Carolina, Ohio, Pennsylvania and Virginia.
Shkreli was sentenced to seven years in prison after being
convicted in 2017 of defrauding investors in two hedge funds he
ran, and scheming to defraud investors in the drugmaker
Retrophin Inc. He was released early from prison last May.
(Reporting by Jonathan Stempel in New York; Editing by Daniel
Wallis)
[© 2023 Thomson Reuters. All rights
reserved.]
This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|
